CLLS Cellectis
- 3.060
- -0.180-5.56%
Cellectis News
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%
European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.60 to 1,414.50 on the S&P Europe Select ADR Index. With the gain, the index is poi
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday
Bank stocks helped European equities traded in the US as American depositary receipts higher late Tuesday morning, rising 0.77% to 1,396.19 on the S&P Europe Select ADR Index. From continental Europe,
AstraZeneca Concludes Equity Investment in Cellectis
Monthly Information on Share Capital and Company Voting Rights
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of
Cellectis Shares Are Trading Higher After the Company Announced the Completion of the Additional Equity Investment by AstraZeneca.
Cellectis Shares Are Trading Higher After the Company Announced the Completion of the Additional Equity Investment by AstraZeneca.
AstraZeneca Invests $140M in Cellectis, Raising Stake to 44%
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
AstraZeneca Secures 44% Stake in French Biotech Cellectis
AstraZeneca (AZN.L, AZN.ST) said Monday it completed its equity investment in Cellectis (ALCLS.PA) and secured a 44% stake in the clinical-stage French biotechnology company.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage
Cellectis Announces Leadership Shift in Finance
Cellectis CFO Bing Wang Retires, Interim CFO Appointed
Cellectis S.A (CLLS) said Thursday that Chief Financial Officer Bing Wang has retired from the company with immediate effect. The company has appointed Arthur Stril as interim CFO. Stril joined Cellec
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Cellectis Announces CFO Departure
Cellectis SAys Bing Wang Is Resigning From His Position as CFO With Immediate Effect
Cellectis SAys Bing Wang Is Resigning From His Position as CFO With Immediate Effect
Cellectis Appoints Arthur Stril as Interim Chief Fincl Officer >CLLS
Cellectis Appoints Arthur Stril as Interim Chief Fincl Officer >CLLS
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Barclays Remains a Buy on Cellectis SA (CLLS)
Cellectis Q4 2023 GAAP EPS $(0.64) Misses $(0.26) Estimate, Sales $1.990M Miss $16.263M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) by 146.15 percent. The company reported quarterly sales of $1.990 million
Analysis
Price Target
No Data
